The goal of this clinical trial is to compare the efficacy of two different daily doses of tetrahydrocannabivarin impregnated mouth strips in healthy non-diabetic obese adults. The main questions to answer are:
Is the low dose treatment superior to placebo for losing weight, abdominal girth, cholesterol levels and blood glucose levels?
Is the low dose treatment superior to placebo for losing weight, abdominal girth, cholesterol levels and blood glucose levels?
Is one dose better than the other dose?
Participants will take either the low dose, high dose or placebo dose daily for ninety days and have physical measurements and blood tests obtained at the beginning and the end of the study.

开始日期2022-01-04

申办/合作机构

Medical Life Care Planners, LLC

NCT02053272 / Completed临床2期

A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes

A study to compare the change in glycaemic control in participants with Type 2 diabetes when treated with GWP42004 or placebo as add-on therapy to metformin over a period of 12 weeks. The safety and tolerability of GWP42004 compared with placebo will also be assessed.

开始日期2014-02-01

申办/合作机构

Jazz Pharmaceuticals Plc

ISRCTN93423464 / CompletedN/AIIT

The effect of delta-9-tetrahydrocannabivarin (THCV) on delta-9-tetrahydrocannabinol (THC): a randomised double-blind crossover study

开始日期2013-03-01

申办/合作机构

King's College London

100 项与 Tetrahydrocannabivarin 相关的临床结果

登录后查看更多信息

100 项与 Tetrahydrocannabivarin 相关的转化医学

登录后查看更多信息

100 项与 Tetrahydrocannabivarin 相关的专利（医药）

登录后查看更多信息

187

项与 Tetrahydrocannabivarin 相关的文献（医药）

2024-01-01·Chemical & pharmaceutical bulletin

Dual Engineering of Olivetolic Acid Cyclase and Tetraketide Synthase for the Formation of Longer Alkyl-Chain Olivetolic Acid Analogs and Their Antibacterial Activities

Review

作者: Morita, Hiroyuki

Among presently used pharmaceuticals, about 60% were developed from natural products with unique chemical diversity and biological activities. Hence, the discovery of new bioactive compounds from natural products is still important for further drug development. In addition, breakthroughs in synthetic biology have also begun to produce many useful compounds through manipulations of the biosynthetic genes for secondary metabolites. Theoretically, this approach can also be exploited to generate new unnatural compounds by intermixing the genes from different biosynthetic pathways and/or engineering the secondary metabolite enzyme(s) with expanded substrate and product specificities. Δ⁹-Tetrahydrocannabinol (Δ⁹-THC), the heat-decarboxylated tetrahydrocannabinolic acid (Δ⁹-THCA) produced by Cannabis sativa, is the most important therapeutic cannabinoid due to its useful pharmacological features, such as analgesic, anti-emetic, anti-inflammatory, and anti-epileptic activities. In the structures of cannabinoids, the resorcinyl alkyl chain is a critical pharmacophore, and the therapeutic effects of Δ⁹-THC can be enhanced by converting the pentyl (C₅) moiety at C-3 to other acyl moieties. Thus, the expansion of unnatural cannabinoids with different C-3 alkyl moiety analogs might establish an excellent platform for the further development of therapeutically beneficial cannabinoids. This article reviews the structure-based dual engineering of both enzymes responsible for the formation of the resorcinyl core of Δ⁹-THC and describes the effect of C-6 alkyl-length extension of olivetolic acid, along with related analogs, on the antibacterial activities against Bacillus subtilis and Staphylococcus aureus.

2023-11-01·Journal of analytical toxicology

Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing

Article

作者: Hayes, Eugene D ; Hart, E Dale ; Jacques, Martin ; Clark, Michael ; Cone, Edward J ; Flegel, Ronald R ; Winecker, Ruth E ; Vikingsson, Svante ; Kuntz, David J

Abstract:

∆8-Tetrahydrocannabinol (∆8-THC) recently became widely available as an alternative to cannabis. ∆8-THC is likely impairing and poses a threat to workplace and traffic safety. In the present study, the prevalence of ∆8-THC in workplace drug testing was investigated by analyzing 1,504 urine specimens with a positive immunoassay cannabinoid initial test using a liquid chromatography–tandem mass spectrometry (LC–MS-MS) method quantifying 15 cannabinoid analytes after hydrolysis. ∆8-tetrahydrocannabinol-9-carboxylic acid (∆8-THC-COOH) was detected in 378 urine specimens (15 ng/mL cutoff), compared to 1,144 specimens containing ∆9-THC-COOH. The data could be divided into three general groups. There were 964 (76%) ∆9-THC-COOH-dominant (<10% ∆8-THC-COOH) and 139 (11%) ∆8-THC-COOH-dominant (>90% ∆8-THC-COOH) specimens, with the remaining 164 (13%) specimens showing a mixture of both analytes (>90% ∆8-THC-COOH). Similar concentrations of ∆9-THC-COOH (median 187 ng/mL) and ∆8-THC-COOH (150 ng/mL) as the dominant species support the use of similar cutoffs and decision rules for both analytes. Apart from the carboxylic acid metabolites, 11-hydroxy-∆9-tetrahydrocannabinol (11-OH-∆9-THC, n = 1,282), ∆9-tetrahydrocannabivarin-9-carboxylic acid (∆9-THCV-COOH, n = 1,058), ∆9-THC (n = 746) and 7-hydroxy-cannabidiol (7-OH-CBD, n = 506) were the most prevalent analytes. Two specimens (0.13%) contained ≥140 ng/mL ∆9-THC without ∆9-THC-COOH, which could be due to genetic variability in the drug-metabolizing enzyme CYP2C9 or an adulterant targeting ∆9-THC-COOH. The cannabinoid immunoassay was repeated, and five specimens (0.33%) generated negative initial tests despite ∆9-THC-COOH concentrations of 54–1,000 ng/mL, potentially indicative of adulteration. The use of ∆8-THC is widespread in the US population, and all forensic laboratories should consider adding ∆8-THC and/or ∆8-THC-COOH to their scope of testing. Similar urinary concentrations were observed for both analytes, indicating that the decision rules used for ∆9-THC-COOH are also appropriate for ∆8-THC-COOH.

2023-10-05·Cannabis and cannabinoid research

Validation and Quantitation of Fifteen Cannabinoids in Cannabis and Marketed Products Using High-Performance Liquid Chromatography-Ultraviolet/Photodiode Array Method.

Article

作者: Elhendawy, Mostafa A ; Ibrahim, Elsayed A ; Chandra, Suman ; Radwan, Mohamed M ; Wanas, Amira S ; ElSohly, Mahmoud A ; Godfrey, Murrell

Background: Cannabis sativa is a psychoactive plant indigenous to Central and South Asia, traditionally used both for recreational and religious purposes, in addition to folk medicine. Cannabis is a rich source of natural compounds, the most important of which are commonly known as cannabinoids that cause a variety of effects through interaction with the endocannabinoid system. Materials and Methods: In this study, a high-performance liquid chromatography-ultraviolet/photodiode array (PDA) method was developed and validated for the analysis of 15 cannabinoids in cannabis plant materials and cannabis-based marketed products. These cannabinoids are cannabidivarinic acid, cannabidivarin, cannabidiolic acid, cannabigerolic acid, cannabigerol, cannabidiol, delta-9-tetrahydrocannabivarin, delta-9-tetrahydrocannabivarinic acid, cannabinol, delta-9-tetrahyrocannabinol, delta-8-tetrahyrocannabinol, cannabicyclol, cannabichromene, delta-9-tetrahyrocannabinolic acid A, and cannabichromenic acid. The separation was carried out using a reversed-phase Luna^® C18(2) column and a mobile phase consisting of 75% acetonitrile and 0.1% formic acid in water. A PDA detector was used, and data were extracted at λ=220 nm. Principal component analysis of cannabis four varieties was performed. Results: The method was linear over the calibration range of 5-75 μg/mL with R²>0.999 for all cannabinoids. This method was sensitive and gave good baseline separation of all examined cannabinoids with limits of detection ranging between 0.2 and 1.6 μg/mL and limits of quantification ranging between 0.6 and 4.8 μg/mL. The average recoveries for all cannabinoids were between 81% and 104%. The measured repeatability and intermediate precisions (% relative standard deviation) in all varieties ranged from 0.35% to 9.84% and 1.11% to 5.26%, respectively. Conclusions: The proposed method is sensitive, selective, reproducible, and accurate. It can be applied for the simultaneous determination of these cannabinoids in the C. sativa biomass and cannabis-derived marketed products.

项与 Tetrahydrocannabivarin 相关的新闻（医药）

2024-06-18

·Outsourcing Pharma

NIH awards Cellibre $2M to advance sustainable cannabinoid ingredient production

This first-of-its-kind phase 2 grant will expedite the commercialization of cannabinoid ingredient production via precision fermentation. The funding aims to develop cost-effective active pharmaceutical ingredients for treating conditions such as appetite suppression, obesity, inflammation, and diabetes. Cellibre, established in 2019 by a team of biomanufacturing innovators, is dedicated to creating a sustainable manufacturing company that utilizes biological processes as production catalysts. “Every cell on Earth functions like a tiny factory, capable of being engineered as a new way to produce chemicals and ingredients in a better, cheaper, and more sustainable way," said Cellibre CEO Ben Chiarelli. "Cellibre harnesses the world’s most elegant manufacturing technology, nature, by moving cellular assembly lines found in natural systems into microorganisms like yeast to create proprietary molecular factories. By feeding these cells nutrients, they produce pure, natural ingredients or chemicals, reducing the need to disrupt ecosystems – creating a revolution in sustainable manufacturing.” Cellibre secures $2 million NIH grant for sustainable cannabinoid production The grant will support the production of high-demand, non-euphoric cannabinoids such as tetrahydrocannabivarin (THCV) and cannabigerol (CBG). THCV is promising for appetite suppression and obesity management, while CBG is being studied for antibacterial properties and potential treatments for cancer and inflammatory diseases. Cellibre’s technology reduces cannabinoid production costs by over ten-fold compared to traditional agricultural methods. Additionally, the environmental impact of growing plants for cannabinoid production is comparable to the greenhouse gas footprint of 15 million cars annually. Cellibre’s approach significantly lowers land, water, and energy use while improving the quality and consistency of these ingredients. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Cannabinoids have significant therapeutic benefits, but manufacturing these ingredients through legacy agriculture is riddled with challenges,” said Cellibre’s Chief Technology Officer, Dr. Spiros Kambourakis. “Our precision fermentation platform solves these problems by using biology to produce high-quality, lower-cost, more sustainable cultured cannabinoids – in essence deploying nature to combat climate change, improve supply chain resilience, and improve human wellness.” Cellibre’s platforms have already shown economic and quality advantages over traditional supply chains. The award will accelerate these advances as Cellibre moves from research and development to full commercialization, focusing on therapeutically relevant cannabinoids. Precision fermentation: The future of cost-effective pharmaceutical ingredients Cellibre’s precision fermentation 'cell factory platform' drastically reduces the greenhouse gas footprint associated with agricultural and petrochemical-based supply chains for various plant-based compounds. The technology ensures a consistent, scalable supply of pharmaceutical-grade ingredients, free from the variability and impurities of agricultural-based production. Beyond cannabinoids, Cellibre’s platform also includes key bioactives for clean beauty and wellness, such as resveratrol, naringenin, bakuchiol, and other functional ingredients. “Biology is the future of manufacturing,” Kambourakis stated. “By moving production from fields to fermentation, we can create products faster, at lower costs, and with higher quality, all while protecting our natural ecosystems.” Innovative bio-manufacturing reduces environmental impact and production costs With the global cannabinoid isolate market projected to surpass $34 billion by 2030 and over 400 active clinical trials in progress, Cellibre’s technologies are crucial for ensuring patient safety and access. Cellibre is a manufacturing technology company that employs an organism-agnostic approach to turn cells into specialized, sustainable factories for large-scale production of globally significant products. The company’s scientific team has led programs from ideation to commercialization, pioneering breakthroughs in energy, ingredients, medicines, and more. Initially, Cellibre focuses on enabling the production of pharmaceutical-grade natural products and bioactives, eliminating the need for agriculture and revolutionizing the sourcing, production, and consumption of these ingredients. Cellibre was founded in 2019 and is headquartered in San Diego, California.

2024-02-27

·BioSpace

Phylos® and People Science® Announce Results of IRB-Backed Controlled Research Study on the Energizing Effects of THCV

Launches Natural Natural™ ingredient brand to raise consumer awareness of naturally-derived rare cannabinoids PORTLAND, Ore., Feb. 27, 2024 /PRNewswire/ -- Cannabis genetics company Phylos®, along with People Science, a direct-to-consumer scientific research and technology company, has conducted an IRB-approved, double-blind clinical research study on the effects of rare cannabinoid tetrahydrocannabivarin (THCV). Results of the study found that Natural Natural™ THCV by Phylos significantly increased energy, activity, motivation, and well-being compared to placebo, without the fatigue and munchies associated with THC consumption. "This study signifies a pivotal moment for the cannabis industry in understanding the effect of THCV in combination with THC," according to Alisha Holloway, PhD, Chief Scientific Officer at Phylos. "The Natural Natural THCV study allows us to leverage our exceptional plants in the advancement of targeted cannabis products, and to chart new territories in understanding the efficacy of natural cannabinoids." Research Results Research participants ingested unmedicated placebo gummies, THC-only gummies, and gummies infused with extract from Get Sh!t Done™ (GSD), a THCV-dominant plant bred by Phylos. The GSD gummies included distillate from the GSD plant with a roughly 2:1 ratio of THCV:THC. Detailed methodology can be found here. The study's core findings include: 20% more participants felt energized after consuming the GSD gummy compared to placebo. 40% more participants reported enjoying their daily activities after consuming the GSD gummy compared to placebo. Participants who consumed the THC-only gummy reported a 50% increase in hunger when taking full doses. Participants who consumed the GSD gummy did not report a statistically significant increase in hunger compared to placebo. Participants who consumed the THC-only gummy reported feeling fatigue three times more than the GSD group. Participants who consumed the GSD gummy reported significantly less fatigue than placebo. Both GSD and THC-only gummies increased activity, exercise performance, motivation, and well-being compared to placebo. Natural Natural™ Brand Launch Phylos announces Natural Natural, the consumer-facing ingredient brand commercializing the company's patented, naturally-derived rare cannabinoid genetics. "Consumers are seeking and deserve access to natural, plant-based wellness products that are backed by science," said Phylos Chief Commercial Officer Whitney Conroy. "Natural Natural is partnering with the industry's top growers, extractors, and brands to ensure customers know the products they purchase are made with the highest quality ingredients with proven effects." Brand partners include some of the industry's top-rated consumer brands including: Yada Yada, Camino, Lost Farms, Heavy Hitters, Kanha, Airgraft, and Garden Society in California; SHRED and Trailblazer in Canada; HiDays in Arizona; Tunnel Vision and Ozone in Illinois, Massachusetts, and New Jersey; Good Day in Maryland; reV in Michigan; Kites and Buddies in Oregon, and Moonlit Cannabis in Washington. Wholesale partners include Pacific Dutch Group and LEEF (CA); Ascend Wellness (IL, MA, NJ); The Pharm (AZ); Common Citizen (MI); Curio Wellness (MD); Schwazze (CO); Buddies (Oregon), with expansion plans into other states and countries in 2024. About Phylos Phylos is a cannabis genetics company that empowers growers of all sizes to produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seed lines that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary, patent-pending technology to provide partners with unparalleled rare cannabinoid genetics. It creates natural, safe, and effective ingredients under its Natural Natural brand utilizing its cultivation, extraction, and formulation expertise. Natural Natural THCV varieties power a high-quality supply chain of naturally derived THCV. About People Science Founded and led by pioneers of decentralized clinical trials, People Science is a technology-enabled clinical research organization with a mission to empower humanity with the tools and knowledge of science and medicine to improve ourselves, our communities, and our world. People Science is building a new people-forward clinical research infrastructure to support the evolution, knowledge, and understanding of alternative, complex, and complementary medicines. The People Science proprietary technology, Chloe (Consumer Health Learning & Organizing Ecosystem), is a consumer-friendly mobile app on the frontend, and a modular and configurable clinical research data management tool on the backend. The platform empowers individuals to answer the question, "Which alternative medicines work best for me?" while making scaled clinical evidence generation easier and more affordable for consumer brands, manufacturers, biotech and biopharma, and academic researchers. Learn more at People Science. Infographic and photos available upon request at Beth Graham, 904-214-6769, 373607@email4pr.com

临床结果

2024-02-20

·PRNewswire

Phylos® Names Whitney Conroy as Chief Commercial Officer

PORTLAND, Ore., Feb. 20, 2024 /PRNewswire/ -- Phylos, a cannabis genetics company advancing the science of cannabis and making large-scale cannabis production profitable and environmentally sustainable, has named Whitney Conroy as Chief Commercial Officer. Conroy will be responsible for all revenue-generating activities of the company and will report to Phylos' Chief Executive Officer Ralph Risch. Continue Reading Whitney Conroy, Chief Commercial Officer "After more than a decade of research and development, Phylos is entering a new era focused on commercializing groundbreaking cannabis genetics that will change the industry landscape. Whitney has a proven track record of strategically positioning companies and products for long-term success, identifying emerging trends and opportunities, and fostering strong teams," according to Risch. "We are thrilled to have her join the Phylos family." Conroy has over fifteen years of experience leading strategic growth projects, building new lines of business, and developing partnerships. Prior to Phylos, Conroy was Vice President of Strategy at Curaleaf where she created business plans for operations in 21 states, spearheaded corporate and social equity partnerships, and led new market expansion and sales initiatives. "Since its inception, Phylos has sought to expand the world's knowledge and acceptance of the cannabis plant," said Conroy. "I am excited and proud to join this exceptional organization as we develop the highest quality genetics that power science-driven, innovative products." About Phylos Phylos is a cannabis genetics company that empowers growers to produce the highest quality cannabis at scale in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seed lines that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary, patent-pending technology to provide partners with unparalleled rare cannabinoid genetics. It creates natural, safe, and effective ingredients under its Natural Natural brand utilizing its cultivation, extraction, and formulation expertise. Natural Natural's THCV varieties power a high-quality supply chain of naturally derived THCV. SOURCE Phylos

高管变更

100 项与 Tetrahydrocannabivarin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11755

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床2期	英国	Jazz Pharmaceuticals Plc	2010-10-01
血脂障碍	临床2期	英国	Jazz Pharmaceuticals Plc	2010-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01217112 (GWMD1092, CTgov)	临床2期	2型糖尿病 \| 血脂障碍	62	GWP42004+GWP42003 (1:1 GWP42003 : GWP42004)	醖鑰觸鏇鬱艱壓鹽夢築(餘獵鹽鏇憲遞鹽蓋製蓋) = 膚膚觸觸鏇簾繭餘鹽鏇艱廠夢範製鏇艱鹽構窪 (觸膚鑰製膚鹽繭壓顧構, 襯衊鹽夢範繭鑰衊遞壓 ~ 襯憲齋範築簾蓋鏇遞鹹) 更多	-	2014-01-20
				GWP42004+GWP42003 (20:1 GWP42003 : GWP42004)	醖鑰觸鏇鬱艱壓鹽夢築(餘獵鹽鏇憲遞鹽蓋製蓋) = 壓齋鬱醖鑰鬱繭顧襯範艱廠夢範製鏇艱鹽構窪 (觸膚鑰製膚鹽繭壓顧構, 繭願壓網顧鏇壓願簾憲 ~ 繭淵積齋築選構艱壓網) 更多